首页> 外文期刊>Pharmacology: International Journal of Experimental and Clinical Pharmacology >Comparative Pharmacokinetic Study of Mangiferin in Normal and Alloxan-Induced Diabetic Rats after Oral and Intravenous Administration by UPLC-MS/MS
【24h】

Comparative Pharmacokinetic Study of Mangiferin in Normal and Alloxan-Induced Diabetic Rats after Oral and Intravenous Administration by UPLC-MS/MS

机译:Mangiferin在HullC-MS / MS口服和静脉内施用后血脂素Mangiferin的比较药代动力学研究

获取原文
获取原文并翻译 | 示例
       

摘要

Backgrounds: Diabetes mellitus (DM)-induced morphological and/or functional complications may alter the pharmacokinetic profiles of mangiferin. This study aims to compare pharmacokinetic profiles of mangiferin in normal and alloxan-induced diabetic rats after oral and intravenous administration. Methods: Mangiferin was administered orally (10 mg/kg) and intravenously (2 mg/kg) to normal and alloxan-induced diabetic Sprague-Dawley (SD) rats (n = 8). Blood samples were collected at different time points post-dose. Mangiferin and esculentoside (internal standard) were analyzed by Waters Acquity ultra-performance liquid chromatography system and TSQ Quantum Ultra triple quadrupole mass spectrometer (UPLC-MS/MS). Results: Mangiferin in normal and alloxan-induced diabetic rats experienced serious first-pass effect, which resulted in 1.71 and 0.80% of oral bioavailability respectively. Meanwhile, mangiferin was predominantly restricted to blood but not extensively distributed to organ tissues after intravenous administration. Compared with normal rats, the diabetic condition induced 53.26 and 50.90% decreases in C-max and AUC(0-t), respectively, for mangiferin after oral administration, and 63.08% decreases in C-max after intravenous administration. Conclusions: Compared to normal rats, pharmacokinetic parameters of mangiferin were altered in diabetic condition induced by alloxan. The findings might help to provide useful evidence for modeling of diabetic rats and the clinical applications of mangiferin. (C) 2018 S. Karger AG, Basel
机译:背景:糖尿病(DM) - 诱导的形态学和/或功能性并发症可能改变Mangiferin的药代动力学谱。本研究旨在比较口服和静脉内施用后正常和阿仑胍诱导的糖尿病大鼠Mangiferin的药代动力学谱。方法:Mangiferin以口服(10mg / kg)和静脉内(2mg / kg)施用至正常和α诱导的糖尿病Sprague-dawley(SD)大鼠(n = 8)。在剂量后的不同时间点收集血样。通过水分,分析Mangiferin和Esculentoside(内标),无菌超级性能液相色谱系统和TSQ量子超三倍四极杆质谱仪(UPLC-MS / MS)。结果:Mangiferin在正常和阿洛昔班诱导的糖尿病大鼠中经历了严重的一流效应,分别导致口腔生物利用度的1.71和0.80%。同时,Mangiferin主要被限制为血液,但在静脉内给药后没有广泛地分配给器官组织。与正常大鼠相比,分别诱导53.26和50.90%的糖尿病病症,分别在口服给药后的Mangiferin诱导53.26和50.90%,并且静脉内给药后C-Max降低63.08%。结论:与正常大鼠相比,体重素的药代动力学参数在阿仑烷诱导的糖尿病病症中改变。调查结果可能有助于为糖尿病大鼠和Mangiferin的临床应用提供有用的依据。 (c)2018年S. Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号